VitaFlow Liberty™ by MicroPort® CardioFlow Medtech Obtains Approval in Argentina

Shanghai, China, 7 January 2022 — MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech) recently announced that its transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has received marketing approval by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

As a new-generation TAVI product, VitaFlow Liberty™ inherits the unique design of the VitaFlow® Transcatheter Aortic Valve and Delivery System (VitaFlow®), with an upgrade to the delivery system. Its unique and innovative double-reinforced spiral structure not only allows for fast, stable and accurate release and retrieval, but also ensures superior flexibility, non-directionality, and 360-degree bending of the valve segment. In addition, VitaFlow Liberty™ is currently the only TAVI product that provides a motorized and retrievable delivery system in the Latin American market.

Since the first overseas implantation at Dr. Julio Mendez Hospital in Argentina in August 2021, VitaFlow® has been successfully used in TAVI procedures in several hospitals in Argentina, establishing a solid foundation for VitaFlow Liberty™ to serve the Argentine market.

In October 2021, CardioFlow Medtech jointly organized a webinar with SOLACI-CACI'21, the largest cardiovascular academic conference in Latin America. The webinar, entitled "Challenges in TAVI-Severe CAD and Coronary Occlusion", was co-chaired by Dr. Diego Grinfeld, President of the CACI and Dr. Jose Alvarez, and brought together specialists from Argentina and China to share their clinical experiences in TAVI treatment at the event. The webinar not only laid a solid academic foundation for the continued development of CardioFlow Medtech in Latin America, but also provided the region with new clinical experience and academic cases in the field of structural heart disease.

The successful launch of VitaFlow Liberty™ in Argentina represents yet another milestone in the internationalization of CardioFlow Medtech. The rapid growth of the VitaFlow® product line in Latin America in the field of valve intervention provides a boost for CardioFlow Medtech to enter more overseas markets with high potential.

In the future, CardioFlow Medtech will continue to accelerate the commercialization of innovative products with international competitiveness and introduce TAVI products to more countries and regions, bringing high-quality, universal total solutions for structural heart disease to more patients around the world.

About CardioFlow Medtech Corporation:

Founded in 2015, Cardioflow Medtech (stock code: 02160), a subsidiary of MicroPort Scientific Corporation (stock code: 00853), focuses on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. In light of today’s enormous, rapidly growing yet severely under-penetrated heart valve medical device market, Cardioflow Medtech has seized this opportunity to strategically focus its product portfolio on the treatment of the most common aortic and mitral valve diseases, including aortic stenosis and mitral regurgitation.